Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular medications two years later, according to an...
Chad Terhune -Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular medications two years later, according to an analysis of U.S. pharmacy claims provided to Reuters that also showed a steady decline in use over time.
Their U.S. prices have drawn fire recently from President Joe Biden and other public officials, who said such drugs could cost the country $411 billion per year if only half of adults with obesity used them. That is $5 billion more than Americans spent on all prescription drugs in 2022. Last year, Prime published data that found 32% of patients were still taking a GLP-1 medicine for weight loss 12 months after their initial prescription. The new data shows that overall, for all the drugs included in the study, only about 15% were still on their medication after two years.
The analysis also found that 26% of patients switched GLP-1 drugs during therapy, perhaps reflecting shortages or changes in insurance coverage, according to Dr. Patrick Gleason, assistant vice president for health outcomes at Prime/MRx and a co-author of the analysis.'NO ONE REALLY KNOWS' Wegovy in March won U.S. approval for reducing the risk of strokes and heart attacks in overweight and obese adults.
Weight Loss Obesity Obese Practice Management Revenue Insurance Health Insurance Health Plans Adherence Adherence To Medication Issues For Patients Compliance Drug Compliance Treatment Adherence Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D GLP-1 Receptor Agonists Glucagon-Like Peptide-1 Receptor Agonists Adverse Effects
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Texas patients turn to clinics for compounded semaglutide with Ozempic and WeGovy scarceAfter Ozempic and Wegovy burst onto the market in 2021 after gaining FDA approval for weight loss, 1 in 8 Americans have tried the pricey medications to cut...
Lire la suite »
Senate panel to weigh Novo Nordisk subpoena on Ozempic, Wegovy pricesThe U.S. Senate health panel said on Tuesday it would vote this month on whether to subpoena Novo Nordisk to answer questions about U.S. prices for weight loss drugs Ozempic and Wegovy, which are far higher than those in other countries.
Lire la suite »
Wegovy and Ozempic Could Spike Risk of Blindness-Causing Condition, Study SaysDigital destination for sophisticated men & women. Live your best life with expert tips and news on health, food, sex, relationships, fashion and lifestyle.
Lire la suite »
GLP-1 Drugs Ozempic, Wegovy Linked to Rare Blinding ConditionTrendy weight-loss drugs appear to increase the risk of a rare and potentially blinding eye condition, a new study warns.
Lire la suite »
Zepbound outperforms Ozempic and Wegovy in head-to-head weight loss studyThe World Health Organization issued an alert on falsified versions of Ozempic, the popular drug used to treat type 2 diabetes and obesity. The WHO warned health care professionals and the public to be aware of the counterfeits, which it said are increasing as demand for the drugs grows. NBC News' Anne Thompson reports.
Lire la suite »
Houston woman first to try Ozempic, Wegovy rival75% of Americans are considered to be overweight, but that number is starting to drop because of popular weight-loss injections.
Lire la suite »